Robert Barrow Sells 19,023 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 19,023 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total value of $721,732.62. Following the completion of the sale, the chief executive officer directly owned 1,494,640 shares of the company’s stock, valued at $56,706,641.60. The trade was a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Robert Barrow also recently made the following trade(s):

• On Thursday, June 25th, Robert Barrow sold 29,208 shares of Definium Therapeutics stock. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24.

Definium Therapeutics Stock Performance

Shares of Definium Therapeutics stock traded up $0.09 during trading on Friday, reaching $38.09. The company’s stock had a trading volume of 1,128,691 shares, compared to its average volume of 2,216,272. The company has a 50-day moving average price of $43.70 and a two-hundred day moving average price of $29.49. Definium Therapeutics, Inc. has a fifty-two week low of $8.77 and a fifty-two week high of $49.70. The firm has a market cap of $5.12 billion, a PE ratio of -11.10 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Analyst Ratings Changes

DFTX has been the subject of several recent research reports. Stifel Nicolaus increased their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Robert W. Baird boosted their price target on Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Canaccord Genuity Group set a $64.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $63.00.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently made changes to their positions in DFTX. California State Teachers Retirement System purchased a new stake in shares of Definium Therapeutics in the second quarter valued at about $283,999,000. Avoro Capital Advisors LLC acquired a new position in shares of Definium Therapeutics during the fourth quarter worth about $66,950,000. Commodore Capital LP raised its holdings in Definium Therapeutics by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after purchasing an additional 475,000 shares in the last quarter. Wellington Management Group LLP purchased a new position in Definium Therapeutics during the second quarter worth about $138,755,000. Finally, Janus Henderson Group PLC lifted its position in Definium Therapeutics by 8,513.2% in the fourth quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company’s stock valued at $32,256,000 after purchasing an additional 2,383,696 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.